Clinical trials: Ocular Hypertension (OHT)
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to TRAVATAN® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.
- Trial name
- NCT01493427
- Testing
- Travoprost 0.004%
- Volunteers
- 202 people
- Sponsor
- Alcon Research
Ocular Hypertension, Glaucoma
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.
- Trial name
- SPORTII (NCT02471105)
- Testing
- Preserved Bimatoprost 0.01%, Tafluprost Unit Dose Preservative Free 15microgram/ml
- Where
- 7 sites in Austria, Belgium and 3 more
- Volunteers
- 67 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in…
- Trial name
- NCT01917383
- Testing
- Trabodenoson, Latanoprost, Timolol
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Open-angle Glaucoma, Oular Hypertension
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in…
- Trial name
- NCT00691717
- Testing
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- Trial name
- NCT05335122
- Testing
- OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
- Where
- 30 sites in United States
- Volunteers
- 83 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma, Open-angle, Ocular Hypertension
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
To compare the intraocular pressure(IOP)-lowering efficacy of morning or evening instillations of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051194
- Testing
- Combination IOP Lowering Therapy
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Efficacy Study of Travoprost APS Versus TRAVATAN
A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00848536
- Testing
- Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution, Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
- Volunteers
- 371 people
- Sponsor
- Alcon Research
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma
Glaucoma is a progressive optic neuropathy that results in a loss of contrast sensitivity and visual field if not detected and treated.
- Trial name
- NCT05075226
- Testing
- Vivity Extended Depth of Focus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
The purpose of this study is to: To evaluate the efficacy of Refrigeration-Free Latanoprost compared to Latanoprost stored at refrigeration temperature with respect to the diurnal intraocular pressure (IOP) change from baseline…
- Trial name
- NCT01430923
- Testing
- refrigeration free latanoprost, latanoprost eye drops
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Aurolab
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Safety Study of Latanoprost Slow Release Insert
This study is a phase 1, open-label, dose-escalation, safety and tolerability study, which will be conducted at one study site. This study will include 3 cohorts. Each cohort will have approximately 5 subjects.
- Trial name
- Latanoprost SR (NCT01180062)
- Testing
- Latanoprost, Arm 2, Latanoprost SR insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Daniel Moore
Glaucoma, OHT - Ocular Hypertension
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments.
- Trial name
- NCT04412096
- Testing
- Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ohio State University
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity
The purpose of this research study is to compare the effect of Netarsudil and Timolol on eye pressure and blood vessels of the back of the eye.
- Trial name
- NCT04064918
- Testing
- Netarsudil 0.02% QD, Timolol maleate 0.5% BID
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Diego
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
AL-54478 Proof of Concept Study
The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01318252
- Testing
- AL-54478 0.005%, Latanoprost 0.005%, AL-54478 Vehicle
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension.
- Trial name
- NCT07641296
- Testing
- BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug)
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan